Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: A meta-analysis of randomized controlled trials

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1839-1845

  Tunio, M A ^a   Hashmi, A ^a   Rafi, M ^a  

^a SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

Author keywords

Disease free survival; Locoregional failure; Meta analysis; Overall survival; Postoperative radiotherapy; Renal cell carcinoma

Indexed keywords

ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; GASTROINTESTINAL DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KIDNEY CARCINOMA; LIVER DISEASE; META ANALYSIS; NEPHRECTOMY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT FAILURE;

EID: 77956160326     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq028     Document Type: Article

References (30)

1. Ljunberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur Urol 2007; 51: 1502-1510.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Pantuck J, Zisman A, Bellderun A. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611-1623.
4. Rabinovith RA, Zelefsky MJ, Gaynor JJ et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994; 12: 206-212.
5. Rafla S. Renal cell carcinoma. Cancer 1970; 25: 26-30.
6. Eilenberger M, Kodyam R, Seyess R. A retrospective study of the results of postoperative radiotherapy of hypernephroma. Radiobiol Radiother (Berl) 1990; 31: 491-496.
7. Scherer E, Wirtz C. The role of postoperative radiotherapy in the treatment of hypernephroid carcinoma. Strahlenther Onkol 1988; 164: 371-385.
8. Finney R. The value of radiotherapy in the treatment of hypernephroma: a clinical trial. Br J Urol 1973; 45: 258-269.
9. Kjaer M, Iversen P, Hvidt V et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by Copenhagen Renal Cell Cancer Study Group. Scand J Urol Nephrol 1987; 21: 285-289.
10. Aref I, Bociek G, Salhani D. Is postoperative radiotherapy for renal cell carcinoma justified? Radiother Oncol 1997; 43: 155-157.
11. Begg CB, Mazumdar M. Operating characteristics of rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
12. Egger M, Smith GD, Schneider M et al. Bias in meta-analysis detected by a simple graphical test. BMJ 1997; 315: 629-634.
13. Ulutin HC, Aksu G, Fayda M et al. The value of postoperative radiotherapy in renal cell carcinoma: a single institution experience. Tumori 2006; 92: 202-206.
14. Safwat A, Shouman T, Hamada E et al. Postoperative radiotherapy improves disease free but not overall survival in high risk cell carcinoma patients. J Egypt Nat Cancer Inst 2000; 12: 17-22.
15. Makarewicz R, Zarzycka M, Kulinska G et al. The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 1998; 45: 380-383.
16. Kao G, Malkowicz SB, Whittington R et al. Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy with CT. Radiology 1994; 193: 725-730.
17. Stein M, Kuten A, Halpern J et al. The value of postoperative irradiation in renal cell cancer. Radiother Oncol 1992; 24: 41-44.
18. Gofrit ON, Shapiro A, Pizov G et al. Does stage T3a renal cell carcinoma embrace a homogeneous group of patients? J Urol 2007; 177: 1682-1686.
19. Yoo C, Song C, Hong JH et al. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. J Urol 2008; 180: 486-491.
20. Fowler J, King CR. Don't squeeze hypofractionated schedules into too-short overall times. Int J Radiat Oncol Biol Phys 2009; 75: 323-325.
21. Fiorino C, Sanguineti G, Valdagni R. Fractionation and late rectal toxicity: no reliable estimates of alpha/beta value for rectum can be derived from studies where different volumes of rectum are irradiated at different dose levels: in regard to Brenner. Int J Radiat Oncol Biol Phys 2004; 60: 1013-1015.
22. Al-mamgani A, Tans L, Van rooij PH et al. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment. Acta Oncol 2009; 48: 562-570.
23. Emami B, Lyman J, Brown A et al. Tolerance of normal tissues to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1999; 21: 109-122.
24. Rafla S, Parikh K. The role of adjuvant radiotherapy in the management of renal cell carcinoma. In Javadpour N (ed), Cancer of the Kidney. New York, NY: Thieme-Stratton 1984; 231.
25. Zhang BX. Postoperative radiotherapy of renal carcinoma: analysis of 57 patients. Zhonghua Zhong Liu Za Zhi 1991; 13: 223-225.
26. Waters WB, Richie JP. Aggressive surgical approach to renal cell carcinoma: a review of 130 cases. J Urol 1979; 122: 306-309.
27. Ramon J, Goldwasser B, Raviv G et al. Long-term results of simple and radical nephrectomy for renal cell carcinoma. Cancer 1991; 67: 2506-2511.
28. Itano NB, Blute ML, Spotts H et al. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000; 164: 322-325.
29. Heng DY, Chi KN, Murray N et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009; 115: 776-783.
30. Lainakis G, Bamias A. Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets 2008; 8: 349-358.